Orexigen Therapeutics
- Pharmaceutical Preparations
- La Jolla, California
Compensation history
Top executives at Orexigen Therapeutics received an average of $2M per person in annual compensation from 2006 to 2016.
Average pay of disclosed executives at Orexigen Therapeutics
By year
- 2015
MN$4MMichael A. NarachiPresident, Chief Executive Officer and Member of the Board of DirectorsTC$3MThomas R. CannellExecutive Vice President, Chief Operating Officer and President of Global Commercial ProductsJH$1MJoseph P. HaganFormer Chief Business and Financial OfficerPK$1MPreston KlassenExecutive Vice President, Global Product DevelopmentHT$894KHeather TurnerFormer Senior Vice President, General Counsel and SecretaryTL$755KThomas P. LynchExecutive Vice President, General Counsel and Secretary- 2014
MN$4MMichael A. NarachiPresident, Chief Executive Officer and Member of the Board of DirectorsJH$2MJoseph P. HaganFormer Chief Business and Financial OfficerMB$2MMark D. BoothChief Commercial Officer outgoingHT$2MHeather TurnerFormer Senior Vice President, General Counsel and SecretaryPK$2MPreston KlassenExecutive Vice President, Global Product Development
Executives
We found 14 executives who work or worked at Orexigen Therapeutics.
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
Thomas Cannell
Orexigen Therapeutics
Chief Operating Officer
Thomas Lynch
Orexigen Therapeutics
General Counsel
Joseph Hagan
Orexigen Therapeutics
Former Chief Business and Financial Officer
Preston Klassen
Orexigen Therapeutics
Executive Vice President, Global Product Development
Heather Turner
Orexigen Therapeutics
General Counsel
Mark Booth
Orexigen Therapeutics
Chief Commercial Officer outgoing
Graham Cooper
Orexigen Therapeutics
Chief Financial Officer
About Orexigen Therapeutics
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryPharmaceutical Preparations
- Address3344 N. Torrey Pines Ct., Suite 200, La Jolla, California 92037
- Phone(858) 875-8600
- Fiscal year endDecember 31
Source: SEC filings on May 30, 2017, May 27, 2016, April 22, 2015, April 27, 2012, April 27, 2011, April 28, 2010, and April 29, 2008.